Skip to search boxSkip to navigationSkip to main content

Toll-like receptor 9–dependent AMPKa activation occurs via TAK1 and contributes to RhoA/ROCK signaling and actin polymerization in vascular smooth muscle cells

  • Cameron G. McCarthy(corresponding author)
    ,
  • Camilla F. Wenceslau
    ,
  • Safia Ogbi
    ,
  • Theodora Szasz
    ,
  • R. Clinton Webb
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Traditionally, Toll-like receptor 9 (TLR9) signals through an MyD88-dependent cascade that results in proinflammatory gene transcription. Recently, it was reported that TLR9 also participates in a stress tolerance signaling cascade in nonimmune cells. In this noncanonical pathway, TLR9 binds to and inhibits sarcoplasmic/endoplasmic reticulum Ca 21 -ATPase 2 (SERCA2), modulating intracellular calcium handling, and subsequently resulting in the activation of 59-AMP–activated protein kinase a (AMPKa). We have previously reported that TLR9 causes increased contraction in isolated arteries; however, the mechanisms underlying this vascular dysfunction need to be further clarified. Therefore, we hypothesized that noncanonical TLR9 signaling was also present in vascular smooth muscle cells (VSMCs) and that it mediates enhanced contractile responses through SERCA2 inhibition. To test these hypotheses, aortic microsomes, aortic VSMCs, and isolated arteries from male Sprague-Dawley rats were incubated with vehicle or TLR9 agonist (ODN2395). Despite clear AMPKa activation after treatment with ODN2395, SERCA2 activity was unaffected. Alternatively, ODN2395 caused the phosphorylation of AMPKa via transforming growth factor b–activated kinase 1 (TAK1), a kinase involved in TLR9 inflammatory signaling. Downstream, we hypothesized that that TLR9 activation of AMPKa may be important in mediating actin cytoskeleton reorganization. ODN2395 significantly increased the filamentous-to-globular actin ratio, as well as indices of RhoA /Rho-associated protein kinase (ROCK) activation, with the latter being prevented by AMPKa inhibition. In conclusion, AMPKa phosphorylation after TLR9 activation in VSMCs appears to be an extension of traditional inflammatory signaling via TAK1, as opposed to SERCA2 inhibition and the noncanonical pathway. Nonetheless, TLR9-AMPKa signaling can mediate VSMC function via RhoA /ROCK activation and actin polymerization.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 60-71 (12 pages)

Journal (Volume, Issue Number)

Journal of Pharmacology and Experimental Therapeutics (Volume 365, Issue 1)

Publication milestones

  • Published - 04/2018

Publication status

Published - 04/2018

ISSN

0022-3565

Publication IDs

  • Scopus: 85043282975
  • PubMed: 29348267

Publication metrics

Metrics

Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
Scopus
citations
SciVal
citations
8
SciVal
FWCI
0.86
SciVal
Author count
5
SciVal
Paper percentile
76

PlumX, opens in new tab

Captures
20
Citation count
17
Mentions
2

Funding Details

This work was supported by the American Heart Association (Grants #13PRE14080019, #14POST20490292, and #15GRNT25700451); the National Institutes of Health National Heart, Lung, and Blood Institute (Grant P01HL134604); and the National Institutes of Health National Institute of General Medical Sciences (Grant K99GM118885). https://doi.org/10.1124/jpet.117.245746.
FundersFunding numbers
NHLBI
P01HL134604
NIGMS
K99GM118885
AHA
14POST20490292, 15GRNT25700451, 13PRE14080019